The startup develops therapeutics for psychiatric disorders using under-researched entheogenic compounds that harness the neuroplastic potential of psychoactive molecules. By advancing from pre-clinical science to clinical trials, the company aims to provide effective treatment options for patients suffering from psychiatric diseases.
Funding
Funding not disclosed
Founders
Product
Problem
Current treatments for psychiatric disorders often have limited efficacy or undesirable side effects. Many entheogenic compounds with potential therapeutic benefits remain under-researched and inaccessible for clinical use. This lack of effective treatment options leaves many patients suffering from debilitating psychiatric conditions.
Solution
Parow Entheobiosciences is developing targeted therapeutics for psychiatric disorders using under-researched entheogenic compounds. The company leverages the neuroplastic effects of psychoactive molecules to create accessible treatments. Their lead compound, a psilocybin-synergistic tryptamine combination (P601), has demonstrated superiority over synthetic psilocybin in pre-clinical studies, including longer duration, increased efficacy in disease models, and increased synaptic plasticity. Parow Entheobiosciences is preparing for clinical trials of P601 in obsessive-compulsive disorder (OCD).
Target Audience
The primary target audience includes individuals suffering from psychiatric disorders, as well as psychiatrists and other healthcare providers seeking more effective and accessible treatment options.
Features
- Lead compound (P601) with demonstrated superiority over synthetic psilocybin in pre-clinical studies
- Dosing schedules and formulations designed to avoid hallucinogenic effects
- Microbial biomanufacturing platform for compound production
- AI-based phenotypic screening in non-human models
- Fully equipped zebrafish laboratory for high-throughput screening
- cGMP-level biomass production facility
- Proprietary extraction, purification, and fractionation technology
- Strong patent position for key indications and bio-manufacturing IP